Sat, October 23, 2021


COVID-19 Vaccine AstraZeneca in Final Stage of Ensuring Highest Quality Assurance for Thailand

AstraZeneca is deeply committed to supporting the Government of Thailand’s efforts to stem the pandemic through timely access to the COVID-19 Vaccine AstraZeneca.

The shipment of COVID-19 Vaccine AstraZeneca which arrived in Thailand on Wednesday 24 February is amongst the first vaccine doses available in the Asia-Pacific. This shipment arrived well ahead of deliveries originally planned in the second quarter of 2021, and was made in special recognition to the Government of Thailand’s exceptional support for vaccine manufacturing for South East Asia. We hope this sends a signal of confidence to the people of Thailand that progress is being made in the fight against the pandemic.
AstraZeneca wishes to clarify that even though the vaccine is now physically present in Thailand, it can only be used once AstraZeneca completes all steps in the Quality Assurance process. Each batch of our vaccine undergoes more than 60 different quality control tests during its journey from manufacture to vaccination. In addition, AstraZeneca works closely with the local Health Authorities to ensure local standards for the Thai people are met. While the process takes time, it is designed to assure every person who is given our vaccine that it is of the same high quality that can be expected from any AstraZeneca product.
AstraZeneca intends to complete all the Quality Assurance steps for this batch by the second week of March as per plan. And AstraZeneca is working extremely hard for the Thai people, and actively collaborating with the Ministry of Public Health so that the vaccine can be delivered and be made available for use on the same day as completion of the Quality Assurance process.
AstraZeneca thanks the people of Thailand for their trust and support, and looks forward to continuing to work closely with the Ministry of Public Health in the interest of the health and prosperity of the people.
AstraZeneca’s COVID-19 vaccine has been granted conditional marketing authorisation or emergency use approval in more than 50 countries by the World Health Organization.

Published : February 27, 2021